Graphite Bio Inc
NASDAQ:LENZ

Watchlist Manager
Graphite Bio Inc Logo
Graphite Bio Inc
NASDAQ:LENZ
Watchlist
Price: 18.29 USD 0.83% Market Closed
Market Cap: 572.3m USD

Operating Margin

-388%
Current
Improving
by 425.6%
vs 3-y average of -813.6%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-388%
=
Operating Income
$-67.9m
/
Revenue
$17.5m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-388%
=
Operating Income
$-67.9m
/
Revenue
$17.5m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Graphite Bio Inc
NASDAQ:LENZ
521.3m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.7B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD
Loading...
No Stocks Found

Market Distribution

Lower than 90% of companies in the United States of America
Percentile
10th
Based on 14 112 companies
10th percentile
-388%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Graphite Bio Inc
Glance View

Market Cap
572.3m USD
Industry
Biotechnology

Graphite Bio, Inc. operates as a clinical-stage gene editing company. The company is headquartered in South San Francisco, California and currently employs 120 full-time employees. The company went IPO on 2021-06-25. The firm has a gene editing platform that is designed to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its research program, GPH102 for the treatment of beta-thalassemia, leverages its gene replacement platform technology by replacing one or both copies of the mutated beta-globin (HBB) gene through HDR to restore HgbA expression to levels. GPH201 is an investigational treatment for X-linked severe combined immunodeficiency syndrome (XSCID), a rare, life-threatening disease where multiple mutations in a single gene (IL2RG) prevent normal immune system function. GPH301 is for the treatment of Gaucher disease. Its pipeline program also includes therapeutic protein production and non-genotoxic conditioning (NGTC).

LENZ Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-388%
=
Operating Income
$-67.9m
/
Revenue
$17.5m
What is Graphite Bio Inc's current Operating Margin?

The current Operating Margin for Graphite Bio Inc is -388%, which is above its 3-year median of -813.6%.

How has Operating Margin changed over time?

Over the last 4 months, Graphite Bio Inc’s Operating Margin has increased from -1 239.2% to -388%. During this period, it reached a low of -1 239.2% on Jun 30, 2025 and a high of -388% on Oct 30, 2025.

Back to Top